Fedratinib Rises

Development of the JAK2 inhibitor fedratinib has restarted after being abruptly stopped in 2013 to investigate instances of the adverse event Wernicke encephalopathy.

 MPNforum Magazine

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.